Pharmaceutical
Pierre Fabre Group is a large private French multinational pharmaceutical organization specializing in rare diseases and oncology. The company is establishing a new US division focused on cellular therapy, with a particular emphasis on innovative treatments for rare and devastating diseases. They are developing tabelecleucel (Tab-cel), an allogeneic cell therapy designed to treat Epstein-Barr Virus Positive Post Transplant Lymphoproliferative Disease (EBV+ PTLD), a rare lymphoma affecting bone marrow and solid organ transplant patients. The company is building a start-up style US organization to commercialize potentially transformative cellular therapies while maintaining patient-centric values.
Beta · Sourced from candidate reports
Be the first to share your experience with Pierre Fabre Group.
Your reply helps other candidates know what to expect.
